Paxlovid COVID Treatment Most Beneficial for Unvaccinated People with Risk Factors. Others May Not Need It
Paxlovid was widely used for COVID treatment but may not be as effective in all cases, particularly for those at low or moderate risk of severe infection.
Ex-Pfizer Employee Convicted for Insider Trades Ahead of Positive Paxlovid Data
A former Pfizer employee has been convicted of insider trading after buying options in the company's stock prior to the announcement of positive Covid-19 drug data.
The employee, Amit Dagar, was a senior statistical program lead for the clinical trial of Pfizer's drug Paxlovid, which showed an 89% reduction in hospitalization or death compared to a placebo.
I'm Young and Healthy. Should I Take Paxlovid?
Paxlovid, an antiviral drug, is beneficial for high-risk individuals in preventing severe COVID-19 outcomes.
Studies suggest that young and healthy individuals without risk factors for severe COVID-19 are unlikely to benefit from taking Paxlovid.
Paxlovid does not lower risk of long-term COVID-19 symptoms, UCSF study shows
Patients who took Paxlovid had similar outcomes to those who did not in terms of long COVID symptoms.
Paxlovid Cuts Covid Death Risk. But Those Who Need It Are Not Taking It.
Low uptake of the effective Covid-19 treatment drug, Paxlovid, has raised concerns among medical researchers.
Doctors' concerns about drug interactions and patients' worries about side effects may contribute to the low usage of Paxlovid.
Rebound Infections Occur in 20% of Paxlovid Users, According to New Research
Around 20% of people taking nirmatrelvir-ritonavir (Paxlovid) for COVID-19 could experience rebound infections.
Patients experiencing rebound infections may still have live virus and can spread it to others.
Previous studies reported lower rebound rates, but a new study specifically investigates the rebound effect.